Jul. 25 at 11:30 PM
$ACET Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001.
Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating the investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy, ADI-001, for autoimmune diseases.
The trial is currently enrolling subjects with SSc, lupus nephritis (LN), and systemic lupus erythematosus (SLE). The Phase I trial comprises four separate arms, with LN and SLE subjects in one group, SSc subjects in another, idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) in the third, and adeno-associated virus (AAV) subjects in the fourth.
